Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says

 
• By Sue Sutter
  
Is the FDA moving the regulatory goalposts for sotagliflozin by searching for benefits beyond reduction in hemoglobin A1C? (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Pathways & Standards